Search
Oruka Therapeutics Inc
ORKAAdd to Watchlist
87.260USD
-7.290-7.71%
Market hours 09/23, 14:04（ET）
5.26BMarket Cap
LossP/E TTM
Oruka Therapeutics Inc (ORKA) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Oruka Therapeutics Inc in the past month.
Strong Buy
7 Strong Buy
7 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
153.154USD+61.28%
ORKA Analyst Recommendation Trends
In the current month, ORKA has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ORKA average Analyst price target in the last month is 153.154.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
14
14
14
14
14
14
ORKA Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
Insmed Inc
INSM
7
17
0
0
0
24
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, ORKA EPS is projected to reach -0.606 in FY2026Q3, following reported EPS of -0.655 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.63
-0.55
-0.52
-0.61
-0.64
Actual
-0.54
-0.58
-0.66
--
--
Surprise
+13.63%
-5.02%
-27.16%
--
--
FAQs
What is Oruka Therapeutics Inc's price target?
Analysts forecast that Oruka Therapeutics Inc's price target is USD 153.15, with the highest forecast at USD 200.00 and the lowest forecast at USD 117.00.
How have Oruka Therapeutics IncORKA's recent earnings per share performed?
The market expectation was USD -0.66, while Oruka Therapeutics IncORKA's earnings per share (EPS) for the previous quarter was USD -0.58. EPS for the next quarter is expected at USD -0.61.
What is the analyst rating for Oruka Therapeutics Inc?
Based on the ratings of Oruka Therapeutics Inc's stock from 14 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.